COMP and adenocarcinoma: The expression of COMP and TAGLN significantly increased during the colorectal normal-adenoma-adenocarcinoma sequence (all p< 0.05), and patients with high expression of COMP and TAGLN had high clinical staging (Figures 5K and S2).